NewGenIvf (NIVF) Current Deferred Revenue (2022 - 2025)

NewGenIvf has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $111981.0 for Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 76.38% year-over-year to $111981.0; the TTM figure through Dec 2025 stood at $111981.0 (up 76.38% YoY), while the FY2025 annual figure was $111981.0, up 76.38% from the prior year.
• Current Deferred Revenue slipped to $111981.0 in Q4 2025, from $67.4 billion in the prior quarter.
• Over the last five years, Current Deferred Revenue for NIVF reached as high as $67.4 billion in Q3 2025 and fell as low as $7937.0 in Q4 2023.
• The 4-year median for Current Deferred Revenue is $89378.5 (2025), against an average of $11.2 billion.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue plunged 99.42% — and 2024, when it surged 699.91%.
• A 4-year view of Current Deferred Revenue shows it stood at $1.4 million in 2022, then plunged by 99.42% to $7937.0 in 2023, then surged by 699.91% to $63489.0 in 2024, then jumped by 76.38% to $111981.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $111981.0, $67.4 billion, and $66776.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.